

# CITATION REPORT

List of articles citing

**Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial**

**DOI: 10.1007/s40259-019-00403-z**  
**BioDrugs, 2020, 34, 197-207.**

**Source:** <https://exaly.com/paper-pdf/77399096/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
6	Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 57-73	5.4	3
5	Budget Impact of Sequential Treatment with Biologics, Biosimilars, and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Thai Patients with Rheumatoid Arthritis. <i>Advances in Therapy</i> , <b>2021</b> , 38, 4885-4899	4.1	0
4	Critical Appraisal and Future Outlook on Anti-Inflammatory Biosimilar Use in Chronic Immune-Mediated Inflammatory Diseases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2022</b> , 152023	5.3	
3	Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience. <i>BioDrugs</i> ,	7.9	0
2	Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis. <b>2022</b> , 8, e002423		0
1	Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study.		0